艾可瑞妥单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 双特异性T细胞接合器 |
| 目标 | CD3E, CD20 |
| 临床资料 | |
| 商品名 | Epkinly, Tepkinly |
| 其他名称 | GEN3013, epcoritamab-bysp |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623023 |
| 核准状况 | |
| 给药途径 | 皮下注射 |
| 药物类别 | 化学疗法 |
| ATC码 | |
| 法律规范状态 | |
| 法律规范 |
|
| 识别信息 | |
| CAS号 | 2134641-34-0 |
| DrugBank | |
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6471H9999N1735O2007S44 |
| 摩尔质量 | 145,624.95 g·mol−1 |
艾可瑞妥单抗（INN：Epcoritamab）是治疗弥漫大B细胞淋巴瘤的皮下注射药品[7]。用于其它治疗失效后的后线治疗[7]。
常见的副作用包括细胞因子释放综合征、疲倦、肌肉骨骼疼痛、注射部位反应、发烧、腹痛、恶心和腹泻[7]。其他副作用包括可能感染和全血球减少症[7]。孕期使用可能对婴儿有害[7]。它是一种单克隆抗体，具双特异性CD20导向CD3 T细胞接合器[7]。
艾可瑞妥单抗于 2023 年在美国取得医疗使用许可[7]。
参考文献
[编辑]- ^ Epkinly Product information. Health Canada. 22 October 2009 [3 March 2024].
- ^ Details for: Epkinly. Health Canada. 18 December 2023 [3 March 2024].
- ^ Summary Basis of Decision (SBD) for Epkinly. Drug and Health Products Portal. 1 September 2012 [9 May 2024].
- ^ Epcoritamab-bysp- epcoritamab injection, solution Epcoritamab-bysp- epcoritamab injection, solution, concentrate. DailyMed. 16 May 2023 [24 May 2023]. （原始内容存档于25 May 2023）.
- ^ Tepkinly Product information. Union Register of medicinal products. 25 September 2023 [1 October 2023].
- ^ Tepkinly EPAR. European Medicines Agency. 5 October 2023 [5 October 2023].
- ^ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 Epcoritamab-bysp- epcoritamab injection, solution Epcoritamab-bysp- epcoritamab injection, solution, concentrate. DailyMed. 16 May 2023 [24 May 2023]. （原始内容存档于25 May 2023）.
延伸阅读
[编辑]- Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Journal of Clinical Oncology. April 2023, 41 (12): 2238–2247. PMC 10115554
. PMID 36548927. doi:10.1200/JCO.22.01725. - van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DR, Hijmering NJ, van Essen HF, de Jong D, Chamuleau ME, Zweegman S, Breij EC, Roemer MG, Mutis T. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer Journal. February 2021, 11 (2): 38. PMC 7892878 . PMID 33602901. doi:10.1038/s41408-021-00430-6.
外部链接
[编辑]- Clinical trial number NCT03625037 for "First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE NHL-1)" at ClinicalTrials.gov
